{"product_id":"biolegend-100241","title":"Biolegend, 100241, Brilliant Violet 711™ anti-mouse CD3 Antibody, 50μg","description":"\u003cp\u003eCD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α\/β or γ\/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide\/MHC antigen complex\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: γδTCR-positive T-T hybridoma D1\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710\/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Arruda DC, et al. 2022. J Control Release. 350:228. PubMed Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed Collin R, et al. 2020. J Immunol. 205:133. PubMed del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed Xu W et al. 2019. Immunity. 50(4):1054-1068 . PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed Challa TD, et al. 2020. Cell Reports. 30(10):3424-3433. PubMed Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed Kaddatz H, et al. 2020. Glia. 69:925. PubMed Silva DA, et al. 2019. Nature. 565:186. PubMed Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed Gangoso E, et al. 2021. Cell. 184:2454. PubMed Boddupalli CS, et al. 2022. Elife. 11:. PubMed\u003cbr\u003e\nRRID: AB_2563945 (BioLegend Cat. No. 100241)\u003cbr\u003e\nStructure: Ig superfamily, CD3\/TCR, 20 kD\u003cbr\u003e\nDistribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells\u003cbr\u003e\nFunction: Antigen recognition, TCR signal transduction, T cell activation\u003cbr\u003e\nLigand\/Receptor: Peptide antigen\/MHC-complex\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.\u003cbr\u003e\nGene ID: 12502\u003cbr\u003e\nUniProt: View information about CD3 on UniProt.org\u003cbr\u003e\nClone: 17A2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T cell antigen receptor complex, T3\u003cbr\u003e\nIsotype: Rat IgG2b, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860825821353,"sku":"100241","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-100241","provider":"Iright","version":"1.0","type":"link"}